Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation

Transplantation

Volumn 94, Issue 9, 2012, Pages 919-924

  Hiemann, Nicola E ^a   Meyer, Rudolf ^a   Wellnhofer, Ernst ^a   Schoenemann, Constanze ^b   Heidecke, Harald ^c   Lachmann, Nils ^b   Hetzer, Roland ^a   Dragun, Duska ^b  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CellTrend GmbH   (Germany)

Author keywords

Heart transplantation; Non HLA antibodies; Pathogenesis; Vasculopathy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTIBODY; ANGIOTENSIN RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C3D; CYCLOSPORIN A; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTIBODY; EVEROLIMUS; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECEPTOR ANTIBODY; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ANTIBODIES; BIOLOGICAL MARKERS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MICROVESSELS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 84869495377     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182692ad2     Document Type: Article

References (31)

1. Bates RL, Frampton G, Rose ML, et al. High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease. Transplantation 2003; 75: 1347.
2. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1Yreceptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
3. Yard B, Spruyt-Gerritse M, Claas F, et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993; 55: 1287.
4. Le Bas-Bernardet S, Hourmant M, Coupel S, et al. Non-HLAYtype endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3: 167.
5. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415.
6. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007; 47: 731.
7. Libby P, Tanaka H. The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Clin Transplant 1994; 8(3 pt 2): 313.
8. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twentyseventh official adult heart transplant reportV2010. J Heart Lung Transplant 2010; 29: 1089.
9. Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantationVevidence from 9,713 endomyocardial biopsies. Circulation 2007; 116: 1274.
10. Warraich RS, Pomerance A, Stanley A, et al. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000; 69: 1609.
11. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.
12. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530.
13. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLAspecific antibody. Am J Transplant 2009; 9: 2136.
14. Yamani MH, Cook DJ, Rodriguez ER, et al. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant 2006; 25: 1283.
15. Yousufuddin M, Cook DJ, Starling RC, et al. Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. J Am Coll Cardiol 2004; 43: 1565.
16. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibodymediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009; 28: 781.
17. Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006; 25: 1277.
18. Hiemann NE, Musci M, Wellnhofer E, et al. Light microscopic biopsy findings after heart transplantation and possible links to development of graft vessel disease. Transplant Proc 1999; 31: 149.
19. Jurewicz M, McDermott DH, Sechler JM, et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin IIYinduced inflammation. J Am Soc Nephrol 2007; 18: 1093.
20. Richter M, Skupin M, Grabs R, et al. New approach in the therapy of chronic rejection? ACE-and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant 2000; 19: 1047.
21. Yamamoto T, Sata M, Fukuda D, et al. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Res Cardiol 2005; 100: 84.
22. Yamamoto T, Sata M, Fukuda D, et al. type 1 receptor blocker candesartan attenuates graft vasculopathy. J Surg Res 2006; 132: 62.
23. Orth SR, Odoni G, Karkoszka H, et al. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. Nephrol Dial Transplant 2003; 18: 62.
24. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783.
25. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
26. Schimmenti LA, Yan HC, Madri JA, et al. Platelet endothelial cell adhesion molecule, PECAM-1, modulates cell migration. J Cell Physiol 1992; 153: 417.
27. Pulford KAF, Rigney EM, Micklem KJ, et al. KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol 1989; 42: 414.
28. Sinclair RA, Burns J, Dunnill MS. Immunoperoxidase staining of formalin-fixed, paraffin-embedded, human renal biopsies with a comparison of the peroxidase-antiperoxidase (PAP) and indirect methods. J Clin Pathol 1981; 34: 859.
29. Kfoury AG, Hammond ME. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 2010; 29: 389.
30. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153.
31. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathyV2010. J Heart Lung Transplant 2010; 29: 717.